Biotech News

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Catalyst Biosciences (CBIO)Catalyst Biosciences2026-05-04 12:48 ESTCommercial

Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases. China innovation engine provides cost-efficient vehicle for discovery and

Catalyst Biosciences

Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.

Recent company news

CBIOCatalyst Biosciences2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

CBIOCatalyst Biosciences2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

CBIOCatalyst Biosciences2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

CBIOCatalyst Biosciences2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

CBIOCatalyst Biosciences2026-05-04 12:48 EST